Why the study?
Recent clinical trials and larger observational studies have provided evidence to tailor thromboprophylaxis approaches for patients with COVID-19, prompting updated guidance.
This document provides updated clinical guidance from the Anticoagulation Forum on thromboprophylaxis strategies for COVID-19 patients across various care settings.
Answers are grounded in this paper and cite their sources.
May support tailored thromboprophylaxis in hospitalized COVID-19; leaves open optimal strategies pending further randomized data.
Thromboembolism is a common and deadly consequence of COVID-19 infection for hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and early observational reports, expert consensus and guidance documents have strongly encouraged the use of prophylactic anticoagulation for patients hospitalized for COVID-19 infection. More recently, multiple clinical trials and larger observational studies have provided evidence for tailoring the approach to thromboprophylaxis for patients with COVID-19. This document provides updated guidance for the use of anticoagulant therapies in patients with COVID-19 from the Anticoagulation Forum, the leading North American organization of anticoagulation providers. We discuss ambulatory, in-hospital, and post-hospital thromboprophylaxis strategies as well as provide guidance for patients with thrombotic conditions who are considering COVID-19 vaccination.
No takes yet. Share an insight, caveat, or question.
Barnes et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: